3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Sarcoma
1
Gynecologic
1
Conditions
Ovarian Neoplasms
69
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Breast Neoplasms
7
Neoplasms
5
Pancreatic Neoplasms
3
Cystadenocarcinoma, Serous
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Prostatic Neoplasms
2
Ovarian Diseases
2
Neoplasm Metastasis
2
Gonadal Disorders
2
Genital Neoplasms, Female
2
Genital Diseases, Female
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Carcinoma
2
Adnexal Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Sarcoma
1
Recurrent/ Advanced Stage Endometrial Cancer Patients
1
Recurrence
1
Prostatic Diseases
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Interventions
pembrolizumab
42
Nivolumab
13
Carboplatin
11
Cyclophosphamide
10
olaparib
7
Paclitaxel
7
Ipilimumab
7
fludarabine
6
Gemcitabine
6
durvalumab
5
lenvatinib
4
cemiplimab
4
atezolizumab
4
Specimen Handling
4
Oxaliplatin
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Fulvestrant
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
veliparib
3
spartalizumab
3
sacituzumab govitecan
3
liposomal doxorubicin
3
avelumab
3
aldesleukin
3
Taxes
3
Interleukin-2
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
niraparib
×
Gynecologic
×
Clear all
NCT02657889
2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2
Completed
122 enrolled
29 charts